revised accounting standards and, therefore, we will be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies.6Table of ContentsThe OfferingCommon stock offered by GlycoMimetics5,750,000 sharesTotal common stock to be outstanding after this offering16,305,497 sharesOption to purchase additional shares of common stockWe have granted the underwriters an option for a period of 30 days from the date of this prospectus to purchase an additional 862,500 shares of our common stock.Use of proceedsWe expect the net proceeds to us from this offering, after expenses, to be approximately $40.3 million, based on an assumed initial public offering price of $8.00 per share.
We intend to use the net proceeds from this offering as follows:napproximately $35.0 million to conduct planned Phase 1 and Phase 1/2 clinical trials of GMI-1271; andnthe remainder to fund the research and development of our preclinical pipeline, including drug discovery, and for working capital and other general corporate
them following the recent completion of our Phase 2 clinical trial, we anticipate that our expenses will increase substantially as we:ncommence clinical trials of GMI-1271;ncontinue the research and development of our other drug candidates;nseek to discover and develop additional drug candidates;nseek regulatory approvals for any drug candidates that successfully complete clinical trials;nultimately establish a sales, marketing and distribution infrastructure and scale up external manufacturing capabilities to commercialize any drugs other than
GMI-1070 for which we may obtain regulatory approval;nmaintain, expand and protect our intellectual property portfolio;nhire additional clinical, quality control and scientific personnel;nadd operational, financial and management information systems and personnel, including personnel to support our drug development and planned future
Phase 1 and Phase 1/2 clinical trials of GMI-1271;nthe number and development requirements of other drug candidates that we may pursue;nthe costs, timing and outcome of regulatory review of our drug candidates;nthe costs and timing of future commercialization activities, including product manufacturing, marketing, sales and distribution, for any of our drug candidates
glycomimetics platform, we will not be able to obtain product revenue in future periods, which likely would result in significant harm to our financial position and adversely affect our stock price.We are very early in our development efforts and have only one drug candidate, GMI-1070, that has completed a clinical trial.
The success of those drug candidates will depend on several factors, including:nsuccessful completion of preclinical studies and clinical trials;nreceipt of marketing approvals from applicable regulatory authorities;nobtaining and maintaining patent and trade secret protection and regulatory exclusivity for our drug candidates;nmaking arrangements with third-party manufacturers for, or establishing, commercial manufacturing capabilities;nlaunching commercial sales of the drugs, if and when approved, whether alone or in collaboration with others;nacceptance of the drugs, if and when approved, by patients, the medical community and third-party payors;neffectively competing with other therapies;nobtaining and maintaining healthcare coverage and adequate reimbursement;nprotecting our rights in our intellectual property portfolio; andnmaintaining a continued acceptable safety profile of the drugs following approval.If we do not achieve one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully commercialize our drug candidates, which would materially harm
experience numerous unforeseen events during, or as a result of, clinical trials that could delay or prevent our or their ability to receive marketing approval or commercialize our drug candidates, including:nregulators or institutional review boards may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective
will continue to develop GMI-1070 in a timely manner, or at all, or, if it achieves regulatory approval, that Pfizer will successfully commercialize GMI-1070.16Table of ContentsOur Pfizer collaboration, and any future collaborations we might enter into, may pose a number of risks, including:ncollaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations;ncollaborators may not perform their obligations as expected;ncollaborators may not pursue the commercialization of any drug candidates that achieve regulatory approval or may elect not to pursue, continue or renew
The degree of market acceptance of our drug candidates, if approved for commercial sale, will depend on a number of factors, including:nthe efficacy and potential advantages compared to alternative treatments;nour ability to offer our drugs for sale at competitive prices;nthe convenience and ease of administration compared to alternative treatments;nthe willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;nthe strength of marketing and distribution support;nthe availability of third-party coverage and adequate reimbursement;19Table of Contentsnthe prevalence and severity of any side effects; andnany restrictions on the use of our drugs together with other medications.If we are unable to establish sales, marketing and distribution capabilities for drug candidates other than GMI-1070, we may not be successful in commercializing those drug candidates if and when they are
personnel.Factors that may inhibit our efforts to commercialize our drugs on our own include:nour inability to recruit, train and retain adequate numbers of effective sales and marketing personnel;nthe inability of sales personnel to obtain access to physicians or persuade adequate numbers of physicians to prescribe any future drugs;nthe lack of complementary drugs to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more products; andnunforeseen costs and expenses associated with creating an independent sales and marketing organization.If we are unable to establish our own sales, marketing and distribution capabilities and enter into arrangements with third parties to perform these services, our
Regardless of merit or eventual outcome, liability claims may result in:ndecreased demand for any drug candidates or drugs that we may develop;ninjury to our reputation and significant negative media attention;nwithdrawal of clinical trial participants;nsignificant costs to defend the related litigation;nsubstantial monetary awards paid to trial participants or patients;nloss of revenue;nreduced resources of our management to pursue our business strategy; andnthe inability to commercialize any drugs that we may develop.22Table of ContentsWe currently hold $5.0 million of product liability insurance coverage in the aggregate, with a per incident limit of
The market price for our common stock may be influenced by many factors, including:nannouncements relating to development, regulatory approvals or commercialization of our drug candidates;nactual or anticipated variations in our operating results;nchanges in financial estimates by us or by any securities analysts who might cover our stock;nconditions or trends in our industry;nchanges in laws or other regulatory actions affecting us or our industry;nstock market price and volume fluctuations of comparable companies and, in particular, those that operate in the biopharmaceutical industry;nannouncements by us or our competitors of significant acquisitions, strategic partnerships or divestitures;nannouncements of investigations or regulatory scrutiny of our operations or lawsuits filed against us;ncapital commitments;ninvestors’ general perception of our company and our business;ndisputes concerning our intellectual property or other proprietary rights;nrecruitment or departure of key personnel; andnsales of our common stock, including sales by our directors and officers or specific stockholders.33Table of ContentsIn addition, in the past, stockholders have initiated class action lawsuits against pharmaceutical and biotechnology
Forward-looking statements include statements about:nour plans to develop and commercialize our glycomimetic drug candidates;nour ability to achieve anticipated milestones under our collaboration with Pfizer for our drug candidateGMI-1070;nour planned clinical trials for our drug candidate GMI-1271;nthe timing of and our ability to obtain and maintain regulatory approvals for our drug candidates;nthe clinical utility of our drug candidates;nour commercialization, marketing and manufacturing capabilities and strategy;nour intellectual property position;nour ability to identify additional drug candidates with significant commercial potential that are consistent with our commercial objectives; andnour estimates regarding future revenues, expenses and needs for additional financing.You should refer to the “Risk Factors” section of this prospectus for a discussion of important factors that may cause our actual results to differ materially from those expressed or implied by our
this prospectus, remains the same.We currently estimate that we will use the net proceeds from this offering as follows:napproximately $35.0 million to conduct planned Phase 1 and Phase 1/2 clinical trials of GMI-1271; andnthe remainder to fund the research and development of our preclinical pipeline, including drug discovery, and for working capital and other general corporate